Common use of No Projections Clause in Contracts

No Projections. Licensor and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Enanta and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Enanta in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR ENANTA NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above in Sections 8.2 and 8.3 or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor in the event such Milestones or and/or Net Sales levels are achieved. NEITHER LICENSOR NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Arvinas and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of whether any Milestone Event will be achieved or of anticipated sales of any Licensed Product, and that the Milestones Milestone Events and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Arvinas in the event the corresponding Milestone Events or such Milestones or Net Sales levels are achieved. NEITHER LICENSOR XXXXXXX NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR MILESTONE EVENT OR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Sangamo and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of whether any Milestone Event will be achieved or of anticipated sales of any Product, and that the Milestones Milestone Events and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Sangamo in the event the corresponding Milestone Events or such Milestones or Net Sales levels are achieved. NEITHER LICENSOR SANGAMO NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR MILESTONE EVENT OR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Vanda and Novartis acknowledge and agree that nothing in this Sublicense Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones milestones and Net Sales levels set forth above or elsewhere in this Sublicense Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties parties are merely intended to define the Milestone Payments milestone and royalty obligations that each party has to Licensor the other in the event such Milestones milestones or Net Sales levels are achieved. NEITHER LICENSOR VANDA NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Company and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Collaboration Product, and that the Milestones and Milestones, Net Sales and Gross Profits levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and or royalty obligations to Licensor in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR NOR NOVARTIS PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT EITHER PARTY WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY COLLABORATION PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR MILESTONE, NET SALES LEVEL OR GROSS PROFIT LEVEL OF SUCH COLLABORATION PRODUCT WILL BE ACHIEVED.

No Projections. Licensor and Novartis The Parties acknowledge and agree that nothing in this Agreement shall will be construed as representing an estimate or projection of anticipated sales of any Licensed Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Cerulean in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR CERULEAN NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Array and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Array in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR ARRAY NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT NOVARTIS, ITS AFFILIATES OR SUBLICENSEES WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor AVEO and Novartis acknowledge and agree that nothing in this Agreement shall will be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor AVEO in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR NOR NOVARTIS MAKES ANY NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Novartis and Novartis Ideaya acknowledge and agree that nothing in this Agreement shall will be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Novartis in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR NOR NOVARTIS IDEAYA MAKES ANY NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

No Projections. Licensor Conatus and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Licensor Conatus in the event such Milestones or Net Sales levels are achieved. NEITHER LICENSOR CONATUS NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT NOVARTIS, ITS AFFILIATES OR SUBLICENSEES WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.